221 related articles for article (PubMed ID: 25583947)
1. Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma.
Jary M; Vernerey D; Lecomte T; Dobi E; Ghiringhelli F; Monnien F; Godet Y; Kim S; Bouché O; Fratte S; Gonçalves A; Leger J; Queiroz L; Adotevi O; Bonnetain F; Borg C
Cancer Epidemiol Biomarkers Prev; 2015 Mar; 24(3):603-12. PubMed ID: 25583947
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score.
Jary M; Lecomte T; Bouché O; Kim S; Dobi E; Queiroz L; Ghiringhelli F; Etienne H; Léger J; Godet Y; Balland J; Lakkis Z; Adotevi O; Bonnetain F; Borg C; Vernerey D
Int J Cancer; 2016 Nov; 139(10):2325-35. PubMed ID: 27472156
[TBL] [Abstract][Full Text] [Related]
3. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
[TBL] [Abstract][Full Text] [Related]
4. Primary tumor location as a prognostic factor in metastatic colorectal cancer.
Loupakis F; Yang D; Yau L; Feng S; Cremolini C; Zhang W; Maus MK; Antoniotti C; Langer C; Scherer SJ; Müller T; Hurwitz HI; Saltz L; Falcone A; Lenz HJ
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25713148
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy.
Jürgensmeier JM; Schmoll HJ; Robertson JD; Brooks L; Taboada M; Morgan SR; Wilson D; Hoff PM
Br J Cancer; 2013 Apr; 108(6):1316-23. PubMed ID: 23449351
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and prognostic potential of serum angiopoietin-2 expression in human breast cancer.
Li P; He Q; Luo C; Qian L
Int J Clin Exp Pathol; 2015; 8(1):660-4. PubMed ID: 25755760
[TBL] [Abstract][Full Text] [Related]
7. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy.
Goede V; Coutelle O; Neuneier J; Reinacher-Schick A; Schnell R; Koslowsky TC; Weihrauch MR; Cremer B; Kashkar H; Odenthal M; Augustin HG; Schmiegel W; Hallek M; Hacker UT
Br J Cancer; 2010 Oct; 103(9):1407-14. PubMed ID: 20924372
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial.
Hacker UT; Escalona-Espinosa L; Consalvo N; Goede V; Schiffmann L; Scherer SJ; Hedge P; Van Cutsem E; Coutelle O; Büning H
Br J Cancer; 2016 Apr; 114(8):855-62. PubMed ID: 27031850
[TBL] [Abstract][Full Text] [Related]
9. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers for the early detection of relapses in metastatic colorectal cancers.
Chereches G; Barbos O; Buiga R; Balacescu O; Iancu D; Todor N; Balacescu L; Miron N; Bejinariu N; Ciuleanu TE
J BUON; 2017; 22(3):658-666. PubMed ID: 28730771
[TBL] [Abstract][Full Text] [Related]
11. Angiopoietin-2 as a Prognostic Factor in Patients with Incurable Stage IV Colorectal Cancer.
Munakata S; Ueyama T; Ishihara H; Komiyama H; Tsukamoto R; Kawai M; Takahashi M; Kojima Y; Tomiki Y; Sakamoto K
J Gastrointest Cancer; 2021 Mar; 52(1):237-242. PubMed ID: 32166589
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of predictive markers for patients with advanced colorectal cancer.
Byström P; Berglund Å; Nygren P; Wernroth L; Johansson B; Larsson A; Glimelius B
Acta Oncol; 2012 Sep; 51(7):849-59. PubMed ID: 22974092
[TBL] [Abstract][Full Text] [Related]
13. The Association of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Thymidine Kinase, and Tissue Polypeptide Specific Antigen with Outcomes of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: a Retrospective Study.
Fiala O; Finek J; Buchler T; Matejka VM; Holubec L; Kulhankova J; Bortlicek Z; Liska V; Topolcan O
Target Oncol; 2015 Dec; 10(4):549-55. PubMed ID: 25875421
[TBL] [Abstract][Full Text] [Related]
14. The Prognostic Value of Serum Semaphorin3A and VEGF Levels in Patients with Metastatic Colorectal Cancer.
Karpuz T; Araz M; Korkmaz L; Kılınc I; Findik S; Karaagaç M; Eryilmaz MK; Artac M
J Gastrointest Cancer; 2020 Jun; 51(2):491-497. PubMed ID: 31218581
[TBL] [Abstract][Full Text] [Related]
15. High baseline Tie1 level predicts poor survival in metastatic breast cancer.
Tiainen L; Korhonen EA; Leppänen VM; Luukkaala T; Hämäläinen M; Tanner M; Lahdenperä O; Vihinen P; Jukkola A; Karihtala P; Aho S; Moilanen E; Alitalo K; Kellokumpu-Lehtinen PL
BMC Cancer; 2019 Jul; 19(1):732. PubMed ID: 31340773
[TBL] [Abstract][Full Text] [Related]
16. The predictive and prognostic value of the Glasgow Prognostic Score in metastatic colorectal carcinoma patients receiving bevacizumab.
Maillet M; Dréanic J; Dhooge M; Mir O; Brezault C; Goldwasser F; Chaussade S; Coriat R
Anticancer Drugs; 2014 Nov; 25(10):1215-9. PubMed ID: 24858536
[TBL] [Abstract][Full Text] [Related]
17. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
[TBL] [Abstract][Full Text] [Related]
18. CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy.
Narita Y; Taniguchi H; Komori A; Nitta S; Yamaguchi K; Kondo C; Nomura M; Kadowaki S; Takahari D; Ura T; Andoh M; Muro K
Cancer Chemother Pharmacol; 2014 Feb; 73(2):409-16. PubMed ID: 24322376
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
[TBL] [Abstract][Full Text] [Related]
20. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
Barbazán J; Muinelo-Romay L; Vieito M; Candamio S; Díaz-López A; Cano A; Gómez-Tato A; Casares de Cal Mde L; Abal M; López-López R
Int J Cancer; 2014 Dec; 135(11):2633-43. PubMed ID: 24752533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]